C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
US10980889B1 · kind B1 · utility
6Cited by
67References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 26, 2020 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Mar 26, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.